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Abstract: A bioactivity guided study of a cf. Caldora penicillata species, collected during
a 2013 expedition to the Pacific island of Saipan, Northern Mariana Islands (a commonwealth
of the USA), led to the isolation of a new thiazoline-containing alkaloid, laucysteinamide A (1).
Laucysteinamide A is a new monomeric analogue of the marine cyanobacterial metabolite,
somocystinamide A (2), a disulfide-bonded dimeric compound that was isolated previously from
a Fijian marine cyanobacterium. The structure and absolute configuration of laucysteinamide A (1)
was determined by a detailed analysis of its NMR, MS, and CD spectra. In addition, the highly
bioactive lipid, curacin D (3), was also found to be present in this cyanobacterial extract. The latter
compound was responsible for the potent cytotoxicity of this extract to H-460 human non-small cell
lung cancer cells in vitro.
Keywords: laucysteinamide A; cyanobacteria; blue-green alga; thiazoline alkaloid; cytotoxicity
1. Introduction
Field collections of Pacific tropical marine cyanobacteria have been a prolific source for a wide
range of novel bioactive marine natural products [1]. Whereas the Northern Mariana Islands have not
previously been identified as “hotspots” of marine biodiversity, their coral reef habitats have been
a source of chemically-prolific strains of marine cyanobacteria. For example, obyanamide, a high nM
LC50 human KB cancer cell cytotoxic agent, was isolated from a collection of the marine cyanobacterium
Lyngbya confervoides from Saipan, a US territory [2]. The relatively unexplored marine biodiversity of
this region is thus an exciting resource for screening for new biologically active natural products.
Such screening efforts are especially relevant to the discovery of anticancer lead compounds,
as many of our current Food and Drug Administration (FDA) approved agents in this therapeutic
class are derived from, or have been patterned after, natural products. Examples include the vinca
alkaloids, taxanes, dolastatins (a lead for auristatin E), and halichondrin B (lead for eribulin) [3], as well
as a number of preclinical leads such as curacin A, discodermolide and the ixabepilone [4]. Common to
all of these agents is their targeting and disruption of the pivotal function of microtubules within
cancer cells, leading to apoptotic cell death.
In 2013, we surveyed the natural populations of marine cyanobacteria from Saipan and made
collections of those present in sufficient biomass to support ensuing chemical and pharmacological
Mar. Drugs 2017, 15, 121; doi:10.3390/md15040121 www.mdpi.com/journal/marinedrugs
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investigations. One such shallow water (1–2 m) collection, obtained from Lau Lau Bay,
comprised several centimeter long tufts of a pinkish-purple colored filamentous cyanobacterium.
These were found growing distinctively from the tops of stipes of the brown alga Turbinaria sp.
Subsequently, the collected biomass was extracted in the laboratory and subjected to a combination
of bioassay and Nuclear Magnetic Resonances (NMR) guided isolation efforts. We describe here the
isolation, structure elucidation, and biological activity of laucysteinamide A (1) (Figure 1), a novel
hybrid PKS/NRPS (2-methyl-4-thiazolinyl) cytotoxic compound from this Saipan cyanobacterial
collection. A second and highly bioactive metabolite of this collection was the previously described
compound curacin D (3), a potent inhibitor of microtubule assembly [5]. Laucysteinamide A is
structurally related to somocystinamide A (2), a neurotoxic and cytotoxic compound (IC50 = 3 nM)
previously isolated from a mixed assemblage of Fijian marine cyanobacteria [6]. In the course of these
studies, the source organism was examined in detail by light microscopy and was found to correspond
to the recently described species Caldora penicillata (Figure 2) [7].
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Figure 1. Structures of Compounds (1–3).
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Figure 2. Microscopic image of filaments of the cf. Caldora penicillata species (100×).
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2. Results and Discussion
SPL-3Feb13-2, a cf. Caldora penicillata collected at Lau Lau Bay in Saipan, was repeatedly extracted
with a 2:1 mixture of dichloromethane (DCM) and methanol (MeOH) to afford a total of 6.73 g of
extract. Two lipophilic fractions obtained from vacuum liquid chromatography of this extract (fraction
C: 20% ethyl acetate (ETAC)/hexanes v/v; fraction D: 40% ETAC/hexanes v/v) possessed interesting
1H-NMR features, such as J-coupled peaks in the alkenyl and typical peptidyl alpha proton regions.
Moreover, they demonstrated strong toxicity in the brine shrimp model (100% toxicity at 3 µg/mL),
and thus were selected for further investigation. These two combined fractions (36.5 mg) were
repeatedly chromatographed by normal phase High Performance Liquid Chromatography (HPLC)
to afford two compounds; 3.6 mg (0.05% extraction yield w/w dry) of compound 1 as an optically
active oil [α]26D = +17.1
◦ (c = 0.86, CHCl3), and 2.7 mg (0.04% extraction yield w/w dry) of compound 3.
Dereplication using MS/MS based molecular networking [8] (Figure 3) and 1H-NMR [5] indicated
that compound 3 was the known cyanobacterial metabolite, curacin D. However, compound 1,
assigned here the trivial name laucysteinamide A, had MS and NMR features unlike any known































mono‐substituted vinylidene moiety,  two di‐substituted  trans alkenes, and  two carbonyl or  imine 
functional groups. At this point, the remaining degree of unsaturation could be explained by either 
the presence of a ring structure or a carbon‐nitrogen triple bond. 
The  substructures  of  an  amide  (1a)  and  a  2‐methyl‐4‐thiazolinyl  ethenyl moiety  (1b) were 
constructed according to  interpretation of 1D and 2D NMR data obtained from  1H‐1H Correlation 
Figure 3. Representative Molecular Network. (Left) the expanded cluster of curacin D includes
one peak in the LC-MS/MS of the present extract along with the node incorporated from a pure
compound library; (Right) the entire molecular network of the crude extract, fractions C–J, and the
pure compound library. The circular cluster represents structurally similar molecular families from
either crude extract or vacuum liquid chromatography (VLC) fractions that share similar MS/MS
fragmentation patterns [8].
The MS of 1 provided a nominal mass of m/z 391 [M + H]+, initially suggesting a molecular
formula typical for a diisooctyl phthalate contaminant (C24H38O4). However, an isotope ratio
fitting calculation eliminated this possibility, and the molecular formula C23H38N2OS was derived
(m/z 391.2778, calcd.; six degrees of unsaturation). A preliminary analysis of 1H- and 13C-NMR spectra
of 1 in C6D6 show resonances for two deshielded methyl groups, amide N-methyl group in
two equilibrating tautomer c c nfigurations [δH 2.90 (s) and 2.35 ppm (s) (3H together, CH3-21)] and
a met yl group attached to an sp2 c rbon [δH 1.98 (3H, s, CH3-23)]. Additionally, eight sp2 carbons
were observed for 1, forming one mono-substituted vinylidene moiety, two di-substituted trans alkenes,
and two carbonyl or imine functional groups. At this point, the remaining degree of unsaturation
could be explained by either the presence of a ring structure or a carbon-nitrogen triple bond.
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The substructures of an amide (1a) and a 2-methyl-4-thiazolinyl ethenyl moiety (1b) were
constructed according to interpretation of 1D and 2D NMR data obtained from 1H-1H Correlation
Spectroscopy (COSY) and 1H-13C Heteronuclear Single Quantum Coherence (HSQC), Heteronuclear 2
Bond Correlation (H2BC), and Heteronuclear Multiple Bond Correlation (HMBC) experiments
(Figure 4). The HSQC data allowed for the assignment of the combined three-proton signals at
δH 2.35 and 2.90 to the cis/trans isomers of the N-methyl amide carbon (δC 31.4 and 29.6, C-21),
respectively. The HMBC correlations from δH 2.35 to the sp2 methine and carbonyl carbons, δC 129.0
(δH 7.80, d, J = 14.4 Hz, C-16) and 170.5 (C-15), respectively, were not observed in the 1H-13C H2BC
spectrum, thus suggesting the occurrence of an N-methyl enamide moiety. For the configurational
isomer with CH3-21 at δH 2.90, HMBC correlations were observed with analogous carbons at δC 130.1
(δH 6.42, d, J = 13.8 Hz) and 170.2. By COSY and J-coupling analysis, the H-16 methine resonances
were located adjacent to another set of divided proton signals [δH 4.61 (dt, J = 13.8, 6.6 Hz) and 4.66
(dt, J = 14.4, 7.2 Hz) (1H together, H-17)], with corresponding carbon resonances at δC 107.2 and 106.9.
The magnitude of the J-coupling between H-16 and H-17 suggested a trans-double bond configuration.
A deshielded methylene group [δH 2.60 (t, J = 6.1 Hz) and 2.68 (t, J = 6.1 Hz) (2H together, H-18),
δC 34.7] was adjacent to C-17 according to H2BC correlations. 1H-1H COSY data sequentially connected
the protons of CH2-18, alkenyl CH-19 [(δH 5.78 (m) and 5.80 ppm (m) (1H together), δC 137.5 and
138.0] and the alkenyl terminus CH2-20 [δH 5.03 (m, 2H), 114.9 and 115.2]. Completing partial structure
1a was a moderately deshielded methylene group at δH 2.09 (2H, t, J = 7.2 Hz), δC 33.6), located next
to the carbonyl by HMBC and H2BC correlations. The two sets of 1H-NMR and 13C-NMR chemical
shift data for each carbon and proton from C-14 to C-21 is explained by conformational anisotropy
caused by cis/trans isomerism of the corresponding N-methyl quaternary imine (Figure 5), as described
previously [6,9]. The cis/trans ratio between these isomers (0.44:1) was calculated in C6D6 at 20 ◦C
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of laucysteinamide A (1). Figure 5. The imine-enamine tautomerism results in two sets of chemical shifts for atoms in this region
of laucysteinamide A (1).
Mar. Drugs 2017, 15, 121 5 of 11
Table 1. NMR Spectroscopic Data for Laucysteinamide A (1) in Benzene-d6.
Position δH Mult. (J in Hz) δC, Mult. (J in Hz) COSY H2BC HMBC
1 3.01, dd (10.8, 8.4) 40.3 2.79, 4.80 79.2 32.7, 79.2, 164.7
2.79, dd (10.8, 8.4) 3.01, 4.80 79.2 164.7
2 4.8, ddd (6.6) 79.2 2.79, 3.01, 1.97, 5.53 40.3 164.7, 130.1, 132.4
3 5.53, dd (15.6, 6.6) 130.1 1.97, 4.80 79.2, 132.4 32.7, 132.4
4 5.69, dt (15.6, 7.8) 132.4 1.97 32.7, 130.1 29.9, 32.7, 130.1
5 1.97, m 32.7 4.80, 5.53/5.69 132.4 40.3
6 1.25, m 29.9 30.0
7 to 12 1.25–1.4, m 30.0
13 1.69, m 25.3 1.28, 1.93, 2.09 33.6 30.0
14 2.09, t (7.2) 33.6 1.69 25.3 30.0
1.93, t (7.8) 34.7 1.69 25.3 170.2
15 170.5
170.2
16 6.42, d (13.8) 130.1 4.61 107.2 34.7, 29.6, 170.5
7.80, d (14.4) 129.0 4.66 106.9 31.4, 34.7
17 4.61, dt (13.8, 6.6) 107.2 2.60, 6.42 129.0 34.7/34.8, 34.7, 129.0, 137.5
4.66, dt (14.4, 7.2) 106.9 2.68, 7.80 137.5 34.7/34.8
18 2.60, t (6.1) 34.7 4.61, 5.78 107.2/106.9 114.9/115.2, 107.2, 130.1, 137.5
2.68, t (6.1) 34.8 4.66, 5.80 114.9/115.2, 106.9, 138.0
19 5.78, m 137.5 2.60, 5.03 114.9 130.1
5.80, m 138.0 2.68, 5.03 115.2 129.0
20 5.03, m 114.9 2.60/2.68 137.5/138.0 34.7/34.8
5.03, m 115.2 2.60/2.68 137.5/138.0 34.7/34.8
21 2.90, s 29.6 6.48 130.1, 107.2/106.9, 170.5
2.35, s 31.4 129.0, 170.5
22 164.7 79.2
23 1.98, s 20.3 164.7
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The remaining unassigned methyl signal from the 1H-NMR spectrum [δH 1.99 ppm (3H,
s, CH3-23)] showed a strong HMBC correlation with an imine carbon [δC 164.7 ppm (C-22)].
A heteroatom-substituted methylene group [δH 3.01 (1H, dd, J = 10.8, 8.4 Hz, H-1a) and 2.79 (1H, dd,
J = 10.8, 8.4 Hz, H-1b)] and a more deshielded methine moiety [δH 4.80 (1H, ddd, J = 6.6 Hz, CH-2),
δC 79.2] also showed HMBC corrections with this imine carbon. By COSY and H2BC, the H2-1 protons
were shown to be adjacent to the C-2 methine, and this could be extended to an alkenyl methine group
[δH 5.53 (1H, dd, J = 15.6, 6.6 Hz, H-3)]. Proton H-3 showed COSY and H2BC correlations with another
vinyl proton [δH 5.69 (1H, dd, J = 15.6, 7.8 Hz, H-4); δC 132.4 (C-4)]; the large J-value between H-3 and
H-4 indicated a trans-relationship. This latter CH group was adjacent to an allylic methylene group (C-5)
as revealed by multiple COSY and HMBC correlations (Figure 4, Table 1). The positioning of a sulfur
between C-23 and C-1 and nitrogen atom between C-23 and C-2 was supported by comparison with the
1H- and 13C-NMR data in benzene-d6 for the 2-alkyl-4-ethenyl-thiazoline moiety present in both curacin
D [5] and curacin A [10]. Altogether, these data suggested the presence of a methylene-substituted
2-methyl-4-ethenyl-thiazoline subunit in laucysteinamide A (1) (Figure 1).
The two partial structures, 1a and 1b, were connected by a saturated linear alkyl chain (1c, C-6
to C-13) to form the final planar structure of compound 1. The insertion of eight methylene groups
between C-5 and C-14 satisfied the molecular formula, and was supported by COSY and HMBC
correlations between the terminal atoms of partial structures 1a and 1b and the shielded methylene
envelope of resonances of partial structure 1c (Figure 4). Consequently, the planar structure of
laucysteinamide (1) was shown to be an alternately condensed form of a monomer of the symmetrical
dimeric metabolite somocysteinamide A (3) [6].
2.1. Stereochemistry
The absolute configuration of laucysteinamide A was determined by comparison of
energy-minimized molecular models of 1 with observed exciton coupling circular dichroism (ECCD)
data. Computational molecular models of enantiomeric forms of 1 were subjected to energy
minimization with MOPAC software (ChemBioDraw Ultra 13.0, PerkinElmer Inc., Waltham, MA,
USA) [11], the results of which are shown in Figure 6. The through-space coupling of nearby interacting
chromophores gives rise to diagnostic angle-dependent exciton coupling in the circular dichroism
spectrum [12]. In the case of laucysteinamide A, a thiazoline chromophore is present in the vicinity
of the C-3/C-4 alkenyl moiety. The coupling of these chromophores gives rise to a corresponding
split Cotton effect, as shown in Figure 6. The ECCD spectrum of compound 1 (Figure S11) showed
a negative local maximum at 223 nm, corresponding to the thiazoline chromophore. The maximum
expected from the C-3/C-4 alkene would be around 190 nm, but was not observed in the spectrum due
to solvent absorptions. However, the CD spectrum clearly showed a negative first Cotton effect, and
thus, the absolute configuration of compound 1 is confidently assigned as 2R. Compound 2, which is
an analogue of compound 1, was assigned previously with a 2R,2′R absolute configuration, and it
showed a similar optical rotation [α]22D = +13.5
◦ (c = 0.75, CHCl3) to compound 1, thus providing
additional support for the absolute configuration of compound 1 as 2R [6].
2.2. Bioactivity
Although laucysteinamide A (1) is structurally analogous to somocystinamide A (2), which was
previously shown to be a potent inhibitor of angiogenesis and cancer cell proliferation (IC50 = 3 nM
against Jurkat leukemia cells [1]), 1 was only mildly cytotoxic to H-460 human non-small cell lung
cancer cells (IC50 = 11 µM), compared with doxorubicin (EC50 = 0.032 µM). Thus, the cytotoxic activity
of this fraction (fraction D) was almost entirely due to the antitubulin properties of curacin D (3) [5].
The brine shrimp toxicity data of all VLC fractions and crude extract are shown in Table S1 in the
supplementary information; unfortunately, compound 1 decomposed before it could be evaluated for
this biological activity.
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2.3. Biosynthetic Considerations
Based on its essentially linear structure, we propose that laucysteinamide A is assembled by
a hybrid PKS/NRPS pathway as it possesses sections logically deriving from amino acid residues
(cysteine and N-methylglycine) and nine acetate units (Figure S12). The assembly of 1 could be
initiated by loading an acetate unit followed by an NRPS-mediated condensation with cysteine,
heterocyclization and dehydration to form the thiazoline ring, followed by six cycles of polyketide
extension. While the first ketide extension is only partially reduced, the ensuing five are fully reduced.
Next, another NRPS module is envisaged to incorporate a glycine residue, followed by an S-adenosyl
methionine assisted methylation of the glycine N-atom (Figure S12). After two more cycles of acetate
extension, the chain termination (Figure S12) likely concludes with a sulfotransferase-aided sulfonate
esterification of the β-hydroxy group, thioesterase hydrolysis and then coincident decarboxylation and
sulfate elimination. This termination sequence is identical to that found in the previously described
curacin A pathway [13].
3. Experimental Section
3.1. General Experimental Procedures
Optical rotations were recorded with a JASCO P-2000 polarimeter; ECCD spectra were measured
in CH2Cl2 using a JASCO J-810 spectropolarimeter (J sc , Easton, MD, USA). UV sp ctr were recorded
with a Beckman Coulter DU800 spectrophoto et r (Indianapolis, IN, USA); IR sp ctra were collected
on a Bruker ALPHA-P FTIR spectrometer w th a diamond ATR (Bruker Optics, Bille ica, MA, USA).
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1H NMR and 2D NMR spectra of laucysteinamide A (1) were measured on the Bruker 600 MHz
NMR spectrometer with a 5 mm inverse detection triple resonance (1H-13C/15N/2D) cryoprobe
(Bruker Biospin, Billerica, MA, USA). The remaining 1H- and 13C-NMR spectra were measured on
a JEOL ECA 500 MHz spectrometer (JEOL, Akishima, Tokyo, Japan) or Varian XSens 2 channel
(1H/13C) NMR cryoprobe optimized for direct observation of 13C-NMR, with samples dissolved in
CDCl3 or C6D6 (Varian, Palo Alto, CA, USA). Low-resolution MS spectra were recorded on a Thermo
Finnigan LCQ, operating in positive ion ESI mode, coupled to a Thermo Finnigan Surveyor Plus
liquid chromatography system (Thermo Scientific, Waltham, MA, USA). HRMS data were obtained
with an Agilent 6230 TOF-MS (Agilent, Santa Clara, CA, USA) under positive ion ESI-TOF-MS
conditions and provided by the University of California, San Diego (UCSD) Small Molecule MS Facility.
Semipreparative HPLC was carried out using a Waters 515 pump system with a Waters 996 PDA
detector (Waters Corporation, Milford, MA, USA).
3.2. Sample Material
A marine cyanobacterial sample, assigned the code SPL-3FEB13-2, was collected in February
2013 from shallow water in Lau Lau Bay, Saipan (GPS coordinates: 15◦09′35.5′ ′ N and 145◦45′25.5′ ′ E).
The taxonomy of the collected sample was determined to be cf. Caldora penicillata by microscopic
characterization. The 2.5–15 cm long cyanobacterial filaments possessed a mucilagenous base and grew
mainly from the tops of Turbinaria sp. The tan/purple colored sample was preserved in approximately
750 mL of isopropanol in sea water at −20 ◦C prior to laboratory extraction. A voucher specimen is
preserved and available from the Gerwick Voucher Collection, Scripps Institution of Oceanography,
University of California San Diego.
3.3. Extraction and Isolation
The sample biomass was defrosted and then extracted with DCM/MeOH (2:1), eight times,
to yield 6.73 g of dark green crude extract. The extracted cyanobacterial biomass was 71.3 g in dry
weight. This crude extract was subjected to a stepped-gradient fractionation (hexanes/EtOAc and
EtOAc/MeOH) by vacuum liquid chromatography (VLC) over normal phase silica gel to give ten
fractions (A–J). Fraction C (eluted with 20% EtOAc/hexanes) was again separated by normal phase
chromatography on silica gel with a stepwise gradient of hexanes/EtOAc to give six sub-fractions
(Ca-Cf). Fraction Cb was further purified by chromatography on a normal-phase Luna HPLC column
(100 Å, 5 µm, 250 × 1000 mm, isocratic solvent system comprised of 10% EtOAc/hexanes over 45 min;
flow rate 3 mL/min; PDA detection) to give 2.7 mg of compound 3 (tR = 13.2 min), which had a pale
yellowish color. The 1H- and 13C-NMR spectra of 3 in C6D6 matched literature reported values for
curacin D [5]. The optical rotation value of 3, [α]25D = +33.3
◦ (c = 0.14, CHCl3), matched the reported
value [α]25D = +33
◦ (c = 0.14, CHCl3) [5].
The 1H-NMR spectrum of fraction D in CDCl3 showed peaks with coupling patterns in the
4.0 ppm to 7.5 ppm region, and was selected for further investigation. The major peak in this fraction
by LC-MS/MS analysis showed an [M + H]+ at m/z 391.11; by MarinLit searching and Molecular
Network analysis, this compound did not correlate with any known compound. Fraction D was
further separated with HPLC as above on a normal-phase Luna column (100 Å, 5 µm, 250 × 1000 mm,
solvent system of a linear gradient starting with 100% 1:3 EtOAc/hexanes for 25 min before being
ramped to 100% 1:1 EtOAc/hexanes in 10 min followed by maintenance in 100% 1:1 EtOAc/hexanes
for another 5 min; flow rate 3 mL/min; PDA detection at 254 nm), giving rise to 3.6 mg of compound 1
(tR = 34.5 min).
3.4. Molecular Networking
The fractions and crude extract were each diluted to 1 mg/mL in MeOH for LC-MS with
automated dependent MS/MS scanning. The following gradient was used: initiated in 50% CH3CN in
MilliQ H2O with 0.1% formic acid (v/v) for 4 min, then CH3CN increased to 99% in a linear gradient
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over 12 min and then maintained at this percentage for 5 min. Finally, the CH3CN was reduced to
50% and stabilized for 3 min. MS data from two scan events were acquired: (1) scan positive MS,
window from m/z 190–2000; (2) scan MS/MS in data-dependent mode for the most intense ions from
the first scan. The raw Thermo XCalibur data files were processed with MSConvert to produce.mxz
files, and these were submitted for molecular networking using the GNPS platform [14]. The resulting
molecular networks were graphically represented using Cytoscape [15].
3.5. Biological Testing
In vitro cytotoxicity studies were performed using H-460 human non-small cell lung cancer cells
as previously described [16]. Briefly, H-460 cells were added to 96-well plates at 3.33 × 104 cells/mL
of Roswell Park Memorial Institute (RPMI) 1640 medium with fetal bovine serum (FBS) and 1%
penicillin/streptomycin. The cells were incubated overnight (37 ◦C, 5% CO2) in a volume of 180 µL per
well to allow recovery before treatment with test compounds. Compounds were dissolved in dimethyl
sulfoxide (DMSO) to a stock concentration of 1 mg/mL. Working solutions were made through serial
dilution in RPMI 1640 medium without FBS, with 20 µL added to each well producing final compound
concentrations of 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, and 0.001 µg/mL. An equal volume of RPMI 1640
without FBS was added to wells designated as negative controls for each plate. Plates were incubated
for approximately 48 h before MTT staining. Plates were read at 570 and 630 nm using a Thermo
Electron Multiskan Ascent plate reader (Thermo Scientific, Waltham, MA, USA).
Brine shrimp toxicity studies were performed as previously described [17]. Briefly, brine shrimp
eggs were hatched for 24 h in brine solution. Each well of the bioassay plate was prefilled with
2 mL brine solution, 200 µL brine shrimp culture mixture (around 15 brine shrimp in brine solution),
and 300 µL brine solution, sequentially. Test fractions and compounds were dissolved and added
to wells in 10 µL DMSO to afford a final concentration of 3 µg/mL and 30 µg/mL in each well,
in duplicate per concentration. A sample of 10 µL DMSO was added to separate wells as a negative
control. After 24 h, the number of dead non-moving brine shrimp was counted with the aid of
a dissecting microscope. Acetone (1.2 mL) was added to each well to sacrifice the shrimp and the total
number of dead shrimp was counted. The difference in the two counts represents the number of live
shrimp at the end of the test period.
Laucysteinamide A (1): pale yellowish oil. [α]26D = +17.07
◦ (c = 0.86, CHCl3); UV λmax (CH2Cl2) 223 nm;
IR (neat) λmax 2927, 2844, 1662, 1634, 1464, 1394, 1338, 1161, 1087, 912 cm−1; 1H-, 13C-, and 2D-NMR see
Table 1; ESIMSm/z 391 [M + H]+; HRESITOFMSm/z 391.2777 [M + H]+ (calcd. for C23H39N2OS, 391.2778).
Curacin D (3): pale yellow oil. [α]25D = +33.3
◦ (c = 0.14, CHCl3), Lit. [α]25D = +33◦ (c = 0.14, CHCl3) [5];
UV λmax (hexanes) 224 (ε 9000) nm 1H-NMR (C6D6, 500 MHz) δ 6.1 (1H, m, H-9), 6.0 (1H, m, H-8),
5.79 (1H, ddt, J = 16.2, 11.0, 7.2 Hz, H-15), 5.64 (1H, dd, J = 10.5, 10.4 Hz, H-3), 5.55 (1H, dt, J = 14.5,
7.1 Hz, H-10), 5.49 (1H, bdt, J = 14.5, 7.3 Hz, H-7), 5.38 (1H, m, H-4), 5.05 (2H, m, H-16), 5.03 (1H, m,
H-2), 3.12 (3H, s, -OMe), 3.05 (1H, m, H-13), 3.03 (1H, dd, J = 10.3, 8.3 Hz, H-1b), 2.74 (1H, dd, J = 10.3,
10.3 Hz, H-1a), 2.2 (4H, m, H-11,14), 2.1 (2H, m, H-5), 2.0 (2H, m, H-6), 1.67 (1H, td, J = 8.3, 5.5 Hz,
H-18), 1.58 (1H, m, H-12a), 1.54 (1H, m, H-12b), 1.17 (3H, d, J = 6.3 Hz, H-21), 1.15 (1H, m, H-19b),
0.95 (1H, m, H-20), 0.67 (1H, ddd, J = 8.1, 8.1, 4.3 Hz, H-19a); 13C-NMR (C6D6, 100 MHz) δ 168.44 (C17),
135.09 (C15), 132.29 (C10), 131.39 (C9), 131.12 (C3), 131.05 (C7), 130.87 (C8), 130.57 (C4), 116.54 (C16),
79.56 (C13), 74.1 (C2), 56.05 (OMe), 39.69 (C1), 37.91 (C14), 33.39 (C12), 32.51 (C6), 28.51 (C11), 27.67 (C5),
19.86 (C18), 15.71 (C20), 13.96 (C19), 12.06 (C21); LC LRMS [M + H]+ m/z 360.114.
4. Conclusions
Marine cyanobacteria, such as Caldora penicillata, are a continuing source of new and bioactive
molecules of interest for natural product drug discovery research. A novel thiazoline containing
alkaloid, laucysteinamide (1), along with known compounds, curacin D (3), were isolated from the
marine cyanobacterium, cf. Caldora penicillata, collected from island of Saipan. Laucysteinamide A (1)
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was determined to be mildly cytotoxic to H-460 human non-small lung cancer cells, and was isolated
together with the known potent bioactive molecule, curacin D (3), which was initially identified by
LC-MS/MS molecular networking dereplication efforts. Laucysteinamide A (1) belongs to a unique
cyanobacterial metabolite class of mixed PKS/NRPS biosynthetic origin, analogous to the previously
reported somocystinamide A (2). We propose that the acetated L-cysteine is extended with six more
malonyl CoA-derived acetate units. This intermediate is then further extended with an N-methyl
glycine unit, followed by two additional acetates. The proposed biosynthesis of 1 is terminated by
a decarboxylation very similar to that described for curacin A [14].
Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/15/4/121/s1,
Figure S1: (a) Fragmentation analysis of curacin D (3). (b) MS of curacin D (3) (positive ion mode). (c) MS/MS
(positive ion mode) spectra of curacin D (3), Figure S2: 1H NMR spectra of curacin D (3) in C6D6, Figure S3:
HPLC chromatogram of laucysteinamide A (1), Figure S4: HRESITOFMS results of laucysteinamide A (1),
Figure S5: 1H NMR spectra of laucysteinamide A (1) in C6D6, Figure S6: 13C NMR spectra of laucysteinamide
A (1) in C6D6, Figure S7: COSY spectra of laucysteinamide A (1) in C6D6, Figure S8: 1H-13C HSQC spectra of
laucysteinamide A (1) in C6D6, Figure S9: H2BC spectra of laucysteinamide A (1) in C6D6, Figure S10: HMBC
spectra of laucysteinamide A (1) in C6D6, Figure S11: ECCD Spectrum of laucysteinamide A (1), Figure S12:
Biosynthetic scheme proposed for laucysteinamide A, Figure S13: (a) Low resolution MS (positive ion mode) of
laucysteinamide A (1). (c) MS/MS (positive ion mode) spectra of 1, Table S1: Brine Shrimp Assay Results of the
10 Fractions (A–J) and Crude Extract of the Sample.
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